These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 20425333)

  • 1. Nodular lymphocyte-predominant Hodgkin's lymphoma.
    Nogovà L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2006 Mar; 1(1):60-5. PubMed ID: 20425333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
    Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
    J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lymphocyte-predominant and classical Hodgkin's lymphoma--comparison of outcomes.
    Nogová L; Reineke T; Josting A; Müller-Hermelink HK; Eich HT; Behringer K; Müller RP; Diehl V; Engert A
    Eur J Haematol Suppl; 2005 Jul; (66):106-10. PubMed ID: 16007877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials.
    Shimabukuro-Vornhagen A; Haverkamp H; Engert A; Balleisen L; Majunke P; Heil G; Eich HT; Stein H; Diehl V; Josting A
    J Clin Oncol; 2005 Aug; 23(24):5739-45. PubMed ID: 16009944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease.
    Diehl V; Sextro M; Franklin J; Hansmann ML; Harris N; Jaffe E; Poppema S; Harris M; Franssila K; van Krieken J; Marafioti T; Anagnostopoulos I; Stein H
    J Clin Oncol; 1999 Mar; 17(3):776-83. PubMed ID: 10071266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodular lymphocyte-predominant Hodgkin lymphoma.
    Fuchs M; Eichenauer DA; Nogová L; Diehl V; Engert A;
    Curr Hematol Malig Rep; 2008 Jul; 3(3):126-31. PubMed ID: 20425457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
    Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
    Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended field radiotherapy, combined modality treatment or involved field radiotherapy for patients with stage IA lymphocyte-predominant Hodgkin's lymphoma: a retrospective analysis from the German Hodgkin Study Group (GHSG).
    Nogová L; Reineke T; Eich HT; Josting A; Müller-Hermelink HK; Wingbermühle K; Brillant C; Gossmann A; Oertel J; Bollen MV; Müller RP; Diehl V; Engert A
    Ann Oncol; 2005 Oct; 16(10):1683-7. PubMed ID: 16093276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biology, clinical course and management of nodular lymphocyte-predominant hodgkin lymphoma.
    Nogová L; Rudiger T; Engert A
    Hematology Am Soc Hematol Educ Program; 2006; ():266-72. PubMed ID: 17124071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of initial characteristics and long-term outcome of patients with lymphocyte-predominant Hodgkin lymphoma and classical Hodgkin lymphoma at clinical stages IA and IIA prospectively treated by brief anthracycline-based chemotherapies plus extended high-dose irradiation.
    Feugier P; Labouyrie E; Djeridane M; Jenabian A; Dubruille V; Berthou C; Ghandour C; Desablens B; Chaït Y; Casassus P; Delwail V; Ifrah N; Le Mevel A; Lamy T; Brière J; Colonna P; Andrieu JM
    Blood; 2004 Nov; 104(9):2675-81. PubMed ID: 15231567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Treatment results of Hodgkin's lymphoma].
    Aleknavicius E; Valuckas KP; Aleknaviciene B; Norkiene L; Smailyte G
    Medicina (Kaunas); 2009; 45(8):615-23. PubMed ID: 19773620
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Progression-free survival of early interim PET-positive patients with advanced stage Hodgkin's lymphoma treated with BEACOPP
    Borchmann P; Haverkamp H; Lohri A; Mey U; Kreissl S; Greil R; Markova J; Feuring-Buske M; Meissner J; Dührsen U; Ostermann H; Keller U; Maschmeyer G; Kuhnert G; Dietlein M; Kobe C; Eich H; Baues C; Stein H; Fuchs M; Diehl V; Engert A
    Lancet Oncol; 2017 Apr; 18(4):454-463. PubMed ID: 28236583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Does bulky disease at diagnosis influence outcome in childhood Hodgkin's disease and require higher radiation doses? Results from the German-Austrian Pediatric Multicenter Trial DAL-HD-90.
    Dieckmann K; Pötter R; Hofmann J; Heinzl H; Wagner W; Schellong G;
    Int J Radiat Oncol Biol Phys; 2003 Jul; 56(3):644-52. PubMed ID: 12788169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
    Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
    Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
    Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
    Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [A retrospective analysis of the treatment results in Hodgkin's disease in a radiotherapy clinic].
    Mjaaland I; Ganser D; Freitag EM; Bohndorf W
    Strahlenther Onkol; 1994 Sep; 170(9):516-23. PubMed ID: 7524173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.
    Engert A; Haverkamp H; Kobe C; Markova J; Renner C; Ho A; Zijlstra J; Král Z; Fuchs M; Hallek M; Kanz L; Döhner H; Dörken B; Engel N; Topp M; Klutmann S; Amthauer H; Bockisch A; Kluge R; Kratochwil C; Schober O; Greil R; Andreesen R; Kneba M; Pfreundschuh M; Stein H; Eich HT; Müller RP; Dietlein M; Borchmann P; Diehl V; ; ;
    Lancet; 2012 May; 379(9828):1791-9. PubMed ID: 22480758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High relapse rate in children with non-advanced nodular lymphocyte predominant Hodgkin's lymphoma (NLPHL or nodular paragranuloma) treated with chemotherapy only.
    van Grotel M; Lam KH; de Man R; Beishuizen A; Pieters R; van den Heuvel-Eibrink MM
    Leuk Lymphoma; 2006 Aug; 47(8):1504-10. PubMed ID: 16966260
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy of early stages Hodgkin's disease. 10 years experience of the Masaryk Memorial Cancer Institute.
    Petera J; Macharová H; Pohanková R; Malír A; Coupek P; Konecný M; Patera J; Pecina J; Drbal J; Koukalová H; Vásová I
    Neoplasma; 2000; 47(2):129-32. PubMed ID: 10985481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.